Clinical Trials Directory

Trials / Terminated

TerminatedNCT04278872

Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
13 (actual)
Sponsor
Sojournix, Inc. · Industry
Sex
Female
Age
40 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study evaluates the efficacy, safety, tolerability, and pharmacokinetics of once daily SJX-653 in postmenopausal women with moderate to severe VMS.

Conditions

Interventions

TypeNameDescription
DRUGSJX-653administered orally once daily
DRUGPlaceboadministered orally once daily

Timeline

Start date
2020-11-09
Primary completion
2021-02-12
Completion
2021-04-07
First posted
2020-02-20
Last updated
2022-01-11
Results posted
2022-01-11

Locations

22 sites across 4 countries: Belgium, Germany, Poland, United Kingdom

Source: ClinicalTrials.gov record NCT04278872. Inclusion in this directory is not an endorsement.

Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms (NCT04278872) · Clinical Trials Directory